The effects of varenicline on attention and inhibitory control among treatment-seeking smokers

Psychopharmacology

Volumn 223, Issue 2, 2012, Pages 131-138

  Rhodes, Jessica D ^a,c   Hawk, Larry W ^a,b   Ashare, Rebecca L ^a   Schlienz, Nicolas J ^a   Mahoney, Martin C ^a,b  

^a UNIVERSITY AT BUFFALO   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Attention; Cognition; Inhibitory control; Smoking; Varenicline

Indexed keywords

PLACEBO; VARENICLINE;

ADULT; AGED; ARTICLE; ATTENTION; ATTENTION DISTURBANCE; CIGARETTE SMOKING; COGNITION; CONTROLLED STUDY; FEMALE; HELP SEEKING BEHAVIOR; HUMAN; INHIBITORY CONTROL; MAJOR CLINICAL STUDY; MALE; MENTAL FUNCTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEX; SMOKING; STEADY STATE; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; ATTENTION; BENZAZEPINES; COGNITION; DRUG ADMINISTRATION SCHEDULE; HUMANS; INHIBITION (PSYCHOLOGY); MIDDLE AGED; NICOTINIC AGONISTS; PATIENT COMPLIANCE; QUINOXALINES; REACTION TIME; SMOKING; SMOKING CESSATION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84866737809     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-012-2700-6     Document Type: Article

References (64)

1. Acheson A, de Wit H (2008) Bupropion improves attention but does not affect impulsive behavior in healthy young adults. Exp Clin Psychopharmacol 16:113-123
2. Adams ZW, Roberts WM, Milich R, Fillmore MT (2011) Does response variability predict distractibility among adults with attention-deficit/ hyperactivity disorder? Psychol Assess 23 (2):427-436
3. American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders, 4th edn, text revision. American Psychiatric Association, Washington, DC
4. Ashare RL, McKee SA (2011) Effects of varenicline and bupropion on cognitive processes among nicotine-deprived smokers. Exp Clin Psychopharmacol 20(1):63-70
5. Band GPH, van der Molen MW, Logan GP (2003) Horse-race model simulations of the stop-signal procedure. Acta Psychol 112:105-142
6. Benowitz NL (2010) Nicotine addiction. N Engl J Med 362 (24):2295-2303
7. Cahill K, Stead, LF, Lancaster T (2011) Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 16(2
8. Coe JW, Brooks PR, Vetelino MG,Wirtz MC, Arnold EP, Huang J et al (2005) Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 48(10):3474-3477
9. Cohen J (1988) Statistical power analysis for the behavioral sciences, 2nd edn. Lawrence Erlbaum, Hillsdale, NJ
10. Conners CK, Levin ED, Sparrow E, Hinton SC, Erhardt D, Meck WH, Rose JE, March JM (1996) Nicotine and attention in adult attention deficit hyperactivity disorder (ADHD). Psychopharmacol Bull 32(1):67-73
11. Cousins MS, Stamat HM, de Wit H (2001) Acute doses of damphetamine and bupropion increase cigarette smoking. Psychopharmacology 157:243-253
12. Daubney, Garrison G, Dugan SE (2009) Varenicline: a first-line treatment option for smoking cessation. Clin Therapeut 31(3
13. Dawkins L, Powell JH, West R, Powell J, Pickering A (2007) A double-blind placebo controlled experimental study of nicotine: II. Effects of response inhibition and executive functioning. Psychopharmacology 190:457-467
14. Dawkins L, Powell JH, Pickering A, Powell J, West R (2009) Patterns of change in withdrawal symptoms, desire to smoke, reward motivation and response inhibition across 3 months of smoking abstinence. Addiction 104(5):850-858
15. de Wit H (2009) Impulsivity as a determinant and consequence of drug use: a review of underlying processes. Addict Biol 14(1):22-31
16. US Food and Drug Administration (2011) FDA drug safety communication: Chantix (varenicline) drug label now contains updated efficacy and safety information. Available at http://www.fda.gov/Drugs/DrugSafety/ucm264436.htm
17. Epstein JN, Langberg JM, Rosen PJ, Graham A, Narad ME, Antonini TN, Brinkman WB, Froehlich T, Simon JO, Altaye M (2011) Evidence for higher reaction time variability for children with ADHD on a range of cognitive tasks including reward and event rate manipulations. Neuropsychology 25(4):427-441
18. Fiore MC, Bailey WC, Cohen SJ et al. (2008) Treating tobacco use and dependence: 2008 update. US Department of Health and Human Services, Public Health Service, May 2008
19. Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, Watsky EJ, Gong J, Willimans KE, Reeves KR (2006) Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs. sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 296(1):47-55
20. Graef S, Schöniknecht P, Sabri O, Hegerl U (2011) Cholinergic receptor subtypes and their role in cognition, emotion, and vigilance control: an overview of preclinical and clinical findings. Psychopharmacology. doi:10.1007/s00213-010-2153-8
21. Hajek P, McRobbie HJ, Myers KE, Stapleton J, Dhanji A (2011) Use of varenicline for 4 weeks before quitting smoking. Arch Intern Med 171(8):770-777
22. Halperin JM, Wolf LE, Pascualvaca DM, Newcorn JH, Healey JM, O'Brien JD, Morganstein A, Young JG (1988) Differential assessment of attention and impulsivity in children. J Am Acad Child Adolesc Psychiatr 27(3):326-329
23. Harris JG, Kongs S, Allensworth D, Martin L, Tregellas J, Sullivan B, Zerbe G, Freedman R (2004) Effects of nicotine on cognitive deficits in schizophrenia. Neuropsychopharmacology 29(7):1378-1385
24. Hawk LW Jr, Ashare RL, Lohnes SF, Schlienz NJ, Rhodes JD, Tiffany ST, Gass JC, Cummings KM, Mahoney MC (2012) The effects of extended pre-quit varenicline treatment on smoking behavior and short-term abstinence: a randomized clinical trial. Clin Pharmacol Ther 91(2):172-180
25. Heishman SJ, Taylor RC, Henningfield JE (1994) Nicotine and smoking: a review of effects on human performance. Exp Clin Psychopharmacol 2:345-395
26. Heishman SJ, Kleykamp BA, Singleton EG (2010) Meta-analysis of the acute effects of nicotine and smoking on human performance. Psychopharmacology. doi:10.1007/s00213-010-1848-1
27. Hendricks PS, Ditre JW, Drobes DJ, Brandon TH (2006) The early time course of smoking withdrawal effects. Psychopharmacology (Berl) 187(3):385-396
28. Hughes JR, Rennard SI, Fingar JR, Talbot SK, Callas PW, Fagerstrom KO (2011) Efficacy of varenicline to prompt quit attempts in smokers not currently trying to quit: a randomized placebocontrolled trial. Nicotine Tob Res 13(10):955-964
29. Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, Billing CB, Gong J, Reeves KR (2006) Efficacy of varenicline, an alpa4beta2 nicotinic acetylcholine receptor partial agonist, vs. placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 296:56-63
30. Kassel JD (1997) Smoking and attention: a review and reformulation of the stimulus-filter hypothesis. Clin Psychol Rev 17(5):451-478
31. Leth-Steensen C, Elbaz ZK, Douglas VI (2000) Mean response times, variability, and skew in the responding of ADHD children: a response time distributional approach. Acta Psychol 104:1167-1190
32. Levin ED, Simon BB (1998) Nicotinic acetylcholine involvement in cognitive function in animals. Psychopharmacology 138:217-230
33. Levin ED, Conners CK, Sparrow E, Hinton S,MechW, Rose JE, Ernhardt D, March J (1996a) Nicotine effects on adults with attention-deficit/hyperactivity disorder. Psychopharmacology 123:55-63
34. Levin E, Wilson W, Rose J, McEvoy J (1996b) Nicotinic-haloperidol interactions and cognitive performance in schizophrenics. Neuropsychopharmacology 15:429-436
35. Lipszyc J, Schachar R (2010) Inhibitory control and psychopathology: a meta-analysis of studies using the stop signal task. J Int Neuropsychol Soc 16:1064-1076
36. Logan GD, Cowan WB (1984) On the ability to inhibit thought and action: a theory of an act of control. Psychol Rev 91(3):295-327
37. Logan GD, Schachar RJ, Tannock R (1997) Impulsivity and inhibitory control. Psychol Sci 8(1):60-64
38. MacDonald S, Nyberg L, Backman L (2006) Intra-individual variability in behavior: links to brain structure, neurotransmission and neuronal activity. Trends Neurosci 29:474-480
39. Matzke D, Wagenmakers EJ (2009) Psychological interpretation of the ex-Gaussian and shifted Wald parameters: a diffusion model analysis. Psychon Bull Rev 16(5):798-817
40. Mitchell SH (1999) Measures of impulsivity in cigarette smokers and non-smokers. Psychopharmacology 146:455-464
41. Newhouse PA, Potter A, Singh A (2004) Effects of nicotine stimulation on cognitive performance. Curr Opin Pharmacol 4:36-46
42. Oncken C, Gonzales D, Nides M, Rennard S, Watsky E, Billing CB, Anziano R, Reeves K (2006) Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med 166(15):1571-1577
43. Oosterlaan I, Logan GD, Sergeant JA (1998) Response inhibition in AD/HD, CD, comorbid AD/HD+CD, anxious, and control children: a meta-analysis of studies with the stop task. J Child Psychol Psychiatry 39(3):411-425
44. Paterson F, Jepson C, Strasser AA, Loughlead J, Perkins KA, Gur RC, Frey JM, Siegel S, Lerman C (2009) Varenicline improves mood and cognition during smoking abstinence. Biol Psychiatry 65:144-149
45. Perkins KA, Mercincavage M, Fonte CA, Lerman C (2010) Varenicline's effects on acute smoking behavior and reward and their association with subsequent abstinence. Psychopharmacology 210(1):45-51
46. Potter AS, Newhouse PA (2004) Effects of acute nicotine administration on behavioral inhibition in adolescents with attention-deficit/hyperactivity disorder. Psychopharmacology 176:182-194
47. Potter AS, Bucci DJ, Newhouse PA (2011) Manipulation of nicotinic acetylcholine receptors differentially affects behavioral inhibition in human subjects with and without disordered baseline impulsivity. Psychopharmacology 220(2):331-340
48. Rennard S, Hughes J, Cinciripini PM, Kralikova E, Raupach T, Arteaga C, St Aubin LB, Russ C (2012) A randomized placebocontrolled trial of varenicline for smoking cessation allowing flexible quit dates. Nicotine Tob Res 14(3):343-350
49. Rezvani AH, Levin ED (2001) Cognitive effects of nicotine. Biol Psychiatry 49:258-267
50. Richards JB, Goncarz AM, Hawk LW Jr (2011) Chapter 2: animal models of behavioral processes that underlie the occurrence of impulsive behaviors in humans. In: Bardo MT, Fishbein DH, Milich R (eds) Inhibitory control and drug abuse prevention: from research to translation. Springer, New York, pp 13-42
51. Rollema H, Chambers LK, Coe JW, Glowa J, Hurst RS, Lebel LA, Lu Y, Mansbach RS, Mather RJ, Rovettie CC, Sands SB, Schaeffer E, Schulz DW, Tingley FD, Williams KE (2007) Pharmacological profile of the α4β2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology 52:985-994
52. Rollema H, Hajós M, Seymour PA, Kozak R,MajchrakMJ, Guanowsky V, Horner WE, Chapin DS, Hoffman WE, Johnson DE, Mclean S, Freeman J, Williams KE (2009) Preclinical pharmacology of the α4β2 nAChR partial agonist varenicline related to effects of reward, mood and cognition. Biochem Pharmacol 78:813-824
53. Sabol KE, Richards JB, Broom SL, Roach JT, Hausknecht K (2003) Effects of stimulus salience and methamphetamine on choice reaction time in the rat: central tendency versus distribution skew. Behav Pharmacol 14:489-500
54. Sarter M, Parikh V, Howe WM (2009) nAChR agonist-induced cognition enhancement: integration of cognitive and neuronal mechanisms. Biochem Pharmacol 78:658-667
55. Segalowitz NS, Segalowitz SJ (1993) Skilled performance, practice, and the differentiation of speed-up from automatization effects: evidence from second language word recognition. Appl Psycholinguist 14:369-385
56. Sheehan DV, Janavs J, Baker R, Harnett-Sheehan K, Knapp E, Sheehan M, Lecrubiery Y, Weiller E, Hergueta T, Amorin P, Bonora LI, Lepine JP (1998) MINI International Neuropsychiatric Interview. J Clin Psychiat 59(Suppl 20):34-57
57. Smith RC, Singh A, Infante M, Khandat A, Kloos A (2002) Effects of smoking and nicotine nasal spray on psychiatric symptoms and cognition in schizophrenia. Neuropsychopharmacology 27:479-497
58. Sofuoglu M (2010) Cognitive enhancement as a pharmacotherapy target for stimulant addiction. Addiction 105(1):38-48
59. Soreni N, Crosbie J, Ickowicz, Schachar R (2009) Stop signal and Conners' continuous performance tasks, test-retest reliability of two inhibition measures in ADHD children. J Atten Disord 13(2):137-143
60. Spencer SV, Hawk LW Jr, Richards JB, Shiels K, Pelham WE Jr, Waxmonsky JG (2009) Stimulant treatment reduces lapses in attention among children with ADHD: the effects of methylphenidate on intra-individual response time distributions. J Abnorm Child Psychol 37:805-816
61. Wagenmakers EJ, Brown S (2007) On the linear relation between the mean and the standard deviation of a response time distribution. Psychol Rev 114(3):830-841
62. West R (1993) Beneficial effects of nicotine: fact or fiction? Addiction 88(5):589-590
63. Wilson SJ, Sayette MA, Fiez JA (2011) Quitting-unmotivated and quitting-motivated cigarette smokers exhibit different patterns of cue-elicited brain activation when anticipating an opportunity to smoke. J Abnorm Psychol
64. Wouda JA, Riga D, De Vries W, Stegeman M, van Mourik Y, Schetters D, Schoffelmeer AN, Pattij T, De Vries TJ (2011) Varenicline attenuates cue-induced relapse to alcohol, but not nicotine seeking, while reducing inhibitory response control. Psychopharmacology (Berl) 216(2):267-277